/**
 * Deep content for /services/{slug} pages — the buyer-intent rebuild (growth plan Phase 1, 2026-10).
 *
 * Every /services/* page crawled on 2026-09-28 was under 2,000 visible words and ranked on page 3+
 * for its head term (`market access services` pos 16.5, `pharma competitive intelligence` pos 69,
 * `quantitative medical market research` pos 44). This module adds the sections a category page needs:
 * an answer-first block, market context, a five-step approach, use cases, a primary-vs-syndicated
 * comparison, scope and pricing, related links and FAQ (rendered as <details>/<summary> with FAQPage schema).
 *
 * Facts policy: regulator names and processes only; the only figures are the published pricing band
 * (/pricing: $10,000–$60,000) and the footprint already stated sitewide (48 countries, 120+ projects a
 * year, 127 in 2025). No invented statistics or client names.
 */
import type { QUALIFICATION_FORM_NEEDS } from '@/data/qualificationFormOptions';

export type ServiceDeepFaq = { question: string; answer: string };

export type ServiceDeepContent = {
  /** Answer-first block for Google AI Overviews and LLM citation. */
  answer: {
    question: string;
    answer: string;
    points: Array<{ title: string; description: string }>;
    summary: string;
  };
  whyNow: { heading: string; paragraphs: string[] };
  approach: { heading: string; intro: string; steps: Array<{ title: string; body: string }> };
  useCases: { heading: string; items: Array<{ title: string; body: string }> };
  compare: {
    heading: string;
    intro: string;
    rows: Array<{ dimension: string; syndicated: string; bionixus: string }>;
  };
  scope: { heading: string; paragraphs: string[] };
  related: { heading: string; links: Array<{ to: string; label: string }> };
  faqs: ServiceDeepFaq[];
  /** Prefills the scoping-call form. */
  defaultNeed: (typeof QUALIFICATION_FORM_NEEDS)[number];
  /** Headline for the scoping-call CTA. */
  ctaHeadline: string;
};

/**
 * Last substantive content change on the six /services/{slug} pages (deep-dive rebuild).
 * Bump this whenever SERVICE_DEEP_CONTENT copy changes — it feeds WebPage.dateModified in JSON-LD.
 */
export const SERVICE_DEEP_CONTENT_MODIFIED_AT = '2026-10-04';
/** First commit of src/pages/ServiceDetail.tsx (git history). */
export const SERVICE_DEEP_CONTENT_PUBLISHED_AT = '2026-02-14';

const FOOTPRINT =
  'BioNixus runs 120+ primary research projects a year (127 in 2025) across 48 countries, with in-house teams in the GCC, Egypt and the UK and vetted fieldwork partners in Europe, the Americas and Asia.';

const PRICING_PARA =
  'Published pricing: most BioNixus primary research projects fall between $10,000 and $60,000 depending on sample, countries and depth. Qualitative programmes with 20–40 interviews sit toward the lower half of the band; multi-country quantitative studies and mixed-method programmes toward the upper half. A scoping call fixes the design and a costed proposal follows within 48 hours.';

export const SERVICE_DEEP_CONTENT: Record<string, ServiceDeepContent> = {
  'quantitative-research': {
    defaultNeed: 'Primary market research',
    ctaHeadline: 'Planning a physician or payer survey?',
    answer: {
      question: 'What is quantitative healthcare market research and when does a pharma team need it?',
      answer:
        'Quantitative healthcare market research measures how many physicians, pharmacists, payers or patients hold a view or behave a certain way, with a sample large enough to report confidence intervals. Pharma and medtech teams commission it when a decision needs a number — share of patients eligible for a new therapy, the price at which prescribing intent falls, or the awareness-trial-usage funnel of a brand against its competitors. BioNixus fields physician, pharmacist and payer surveys across the GCC, Egypt, Turkey, the UK, EU5, the US and Asia with specialty-verified respondents and Arabic–English instruments.',
      points: [
        {
          title: 'Specialty-verified samples',
          description:
            'Respondents are screened on specialty, patient volume and institution type, then verified against registries and licence lists before they count toward quota.',
        },
        {
          title: 'Decision-grade methods',
          description:
            'Conjoint, MaxDiff, discrete-choice, Van Westendorp and Gabor-Granger designs, TURF and segmentation, chosen for the decision rather than the deck.',
        },
        {
          title: 'Multi-country comparability',
          description:
            'One master instrument, local adaptation reviewed by medical advisors, and harmonised coding so a UAE cell reads against a UK or German cell.',
        },
        {
          title: 'Account-level read-outs',
          description:
            'Where the question is commercial, results are cut by hospital group, pharmacy chain or payer so brand teams can act account by account.',
        },
      ],
      summary:
        'BioNixus is the primary-research complement to syndicated audit data: IQVIA tells you what was sold; a BioNixus survey tells you why, by whom, and what would change it.',
    },
    whyNow: {
      heading: 'Why quantitative evidence decides more launches now',
      paragraphs: [
        'Access bars have risen in every priority market. In Saudi Arabia the SFDA Economic Evaluation System, mandatory since 1 July 2025, expects budget-impact and cost-effectiveness inputs at registration; NUPCO centralised tenders set the volume a brand can win in public hospitals; MOHAP, DHA and DOH listing committees in the UAE each ask for local evidence. A physician survey sized for the committee question, not just the brand plan, is now part of the access file.',
        'Syndicated audits report what was sold last quarter but cannot explain the gap between a brand\u2019s share and its potential. Quantitative ATU, demand-estimation and pricing studies close that gap by measuring awareness, perceived differentiation, eligible patient pools and price elasticity among the physicians who actually prescribe in the target accounts.',
        'Launch windows are shorter. With biosimilar and generic entry compressing exclusivity, teams need baseline and six-month tracking waves that read quickly and roll up across countries. Online physician panels in the GCC and Egypt remain thin, so BioNixus blends online, telephone and in-clinic recruitment to reach quota without inflating cost.',
        'Finally, HQ expects comparability. Regional affiliates that commission one-off local surveys struggle to defend findings against global benchmarks. A harmonised instrument fielded by one agency across the GCC, Europe and Asia produces data that global marketing, medical and access teams can use in the same model.',
      ],
    },
    approach: {
      heading: 'How a BioNixus quantitative study runs',
      intro:
        'A typical single-country physician survey of 100–150 respondents reports in six to eight weeks; multi-country programmes run in parallel cells.',
      steps: [
        {
          title: '1. Scoping call and decision brief',
          body:
            'A 30-minute call converts the business question into a decision brief: the decision, the metric that would change it, the stakeholder groups that hold the answer and the precision required. This fixes sample size, method and markets before any design work starts.',
        },
        {
          title: '2. Instrument design and medical review',
          body:
            'Questionnaires are drafted with the client\u2019s medical and legal teams, pre-tested with three to five target physicians, and reviewed by a local advisor in each country for terminology, clinical pathway realism and compliance with local promotional codes.',
        },
        {
          title: '3. Recruitment, screening and verification',
          body:
            'Recruitment combines proprietary physician and pharmacist databases, hospital-level outreach and partner panels. Screeners enforce specialty, patient volume and sector quotas; identities are verified against medical councils and licensing bodies before incentives are released.',
        },
        {
          title: '4. Fieldwork with daily quality control',
          body:
            'Fieldwork runs online, by telephone or in clinic depending on specialty reachability. Speeders, straight-liners and inconsistent responders are flagged daily; quotas are monitored by country so no cell closes short.',
        },
        {
          title: '5. Analysis, modelling and read-out',
          body:
            'Weighting, significance testing and advanced analytics (conjoint utilities, segmentation, driver analysis) are documented in a methodology appendix. Findings are presented as decisions, not charts, with a 30/60/90-day action plan and the raw data delivered for internal modelling.',
        },
      ],
    },
    useCases: {
      heading: 'What pharma and medtech teams measure with BioNixus',
      items: [
        {
          title: 'Demand estimation and forecasting inputs',
          body: 'Eligible patient pool, share of prescriptions a new therapy would capture, and time to adoption by segment, fed directly into launch forecasts.',
        },
        {
          title: 'Pricing and reimbursement research',
          body: 'Van Westendorp price-sensitivity meters, Gabor-Granger demand curves and payer willingness-to-pay studies that set launch price corridors and tender bids.',
        },
        {
          title: 'ATU and brand tracking',
          body: 'Awareness, trial, usage and message recall tracked in waves across GCC, Egypt and European markets so brand teams see movement by country and account.',
        },
        {
          title: 'Message and concept testing',
          body: 'Monadic and sequential-monadic tests of value propositions and detail aids with the physicians the sales force will meet.',
        },
        {
          title: 'Segmentation and targeting',
          body: 'Attitudinal and behavioural segments of prescribers linked to institution type so field teams know which accounts to prioritise.',
        },
        {
          title: 'Medical device and diagnostics adoption',
          body: 'Procurement committee, biomedical engineer and clinician surveys on device preference, switching barriers and tender criteria.',
        },
      ],
    },
    compare: {
      heading: 'Primary quantitative research vs syndicated audit data',
      intro:
        'Teams rarely choose between the two; they pair them. The table shows what each answers so the brief lands on the right instrument.',
      rows: [
        { dimension: 'Question answered', syndicated: 'What was sold, where, in what volume', bionixus: 'Why, by whom, and what would change behaviour' },
        { dimension: 'Unit of analysis', syndicated: 'Pack, molecule, channel', bionixus: 'Physician, pharmacist, payer, account' },
        { dimension: 'Coverage of GCC and Egypt', syndicated: 'Retail and partial hospital audit', bionixus: 'Public and private hospital, retail and payer stakeholders, bilingual' },
        { dimension: 'Timing', syndicated: 'Monthly or quarterly, retrospective', bionixus: 'Scoped to the decision: 6–8 weeks, forward-looking' },
        { dimension: 'Ownership', syndicated: 'Licensed, shared across subscribers', bionixus: 'Client-owned data and instrument' },
      ],
    },
    scope: {
      heading: 'Scope, timelines and pricing',
      paragraphs: [
        PRICING_PARA,
        'Single-country physician surveys of 100–150 respondents typically report in six to eight weeks. Multi-country programmes run in parallel cells with a harmonised master questionnaire; adding a country adds fieldwork cost, not calendar time. ' + FOOTPRINT,
      ],
    },
    related: {
      heading: 'Related BioNixus pages',
      links: [
        { to: '/healthcare-market-research', label: 'Healthcare market research hub: markets, methods and who to brief' },
        { to: '/quantitative-healthcare-market-research', label: 'Quantitative healthcare market research methodology guide (2026)' },
        { to: '/services/market-access', label: 'Market access consulting for GCC and EMEA payers' },
        { to: '/iqvia-alternative', label: 'IQVIA alternatives and competitors compared for pharma' },
        { to: '/pricing', label: 'Published pricing bands for primary research' },
      ],
    },
    faqs: [
      {
        question: 'What sample size do we need for a physician survey?',
        answer:
          'It depends on the decision. Directional reads on awareness or preference are reliable at 50–75 specialists per country; pricing, conjoint and segmentation work normally needs 100–200. BioNixus calculates the sample during the scoping call from the precision the decision requires and the specialty\u2019s reachable universe in each market.',
      },
      {
        question: 'Can you reach specialists in Saudi Arabia, the UAE and Egypt online?',
        answer:
          'Partly. Online panels are thin for many specialties in the GCC and Egypt, so BioNixus blends online invitations with telephone and in-clinic recruitment through its own physician databases and hospital relationships. This keeps quotas achievable and reduces the professional-respondent bias common in panel-only studies.',
      },
      {
        question: 'How do you verify that respondents are real, practising physicians?',
        answer:
          'Screeners enforce specialty, years in practice and monthly patient volume; identities are checked against medical council and licensing records before incentives are paid; and in-survey consistency checks remove speeders and straight-liners. Verification rates are reported in the methodology appendix.',
      },
      {
        question: 'Do you run conjoint and discrete-choice experiments?',
        answer:
          'Yes. BioNixus designs choice-based conjoint, MaxDiff and discrete-choice experiments for product-profile, pricing and tender-criteria questions, with simulators delivered so brand teams can test scenarios after the read-out.',
      },
      {
        question: 'How does this complement IQVIA or other syndicated data?',
        answer:
          'Syndicated audits show sales volumes by pack and channel; they cannot explain prescriber motivation or predict response to a new price or message. BioNixus surveys supply the behavioural and attitudinal layer, cut by the same accounts, so teams can act on the gap between share and potential.',
      },
      {
        question: 'How long does a quantitative study take and what does it cost?',
        answer:
          'Single-country studies of 100–150 physicians report in six to eight weeks. Published pricing runs from $10,000 to $60,000 depending on countries, sample and analytics; a costed proposal follows the scoping call within 48 hours.',
      },
    ],
  },

  'qualitative-research': {
    defaultNeed: 'Primary market research',
    ctaHeadline: 'Planning KOL, physician or patient interviews?',
    answer: {
      question: 'What does qualitative pharmaceutical market research deliver that surveys cannot?',
      answer:
        'Qualitative pharmaceutical research explains behaviour: why a specialist delays switching to a new biologic, how a payer committee weighs a budget-impact argument, where a patient journey breaks between diagnosis and treatment. It uses in-depth interviews, focus groups, advisory boards and ethnography with small, carefully selected samples, and it is the right first step when a team does not yet know which hypotheses a survey should test. BioNixus moderates in Arabic and English across the GCC, Egypt and Turkey, and in local languages across the UK, EU5 and Asia.',
      points: [
        {
          title: 'Senior moderation',
          description: 'Interviews are led by researchers with pharma category experience, not junior recruiters, so probing follows clinical logic.',
        },
        {
          title: 'Hard-to-reach stakeholders',
          description: 'KOLs, hospital pharmacists, procurement heads, payer advisors and patients recruited through hospital relationships rather than panels.',
        },
        {
          title: 'Bilingual by design',
          description: 'Discussion guides are transcreated, not translated; verbatims are delivered in the original language and English.',
        },
        {
          title: 'Structured outputs',
          description: 'Thematic frameworks, journey maps and message hierarchies that feed quantitative validation or go straight into strategy.',
        },
      ],
      summary: 'BioNixus qualitative work is designed to be followed by a decision: a quantitative test, a revised value story or a changed field plan.',
    },
    whyNow: {
      heading: 'Why qualitative insight is the first step in priority markets',
      paragraphs: [
        'Treatment pathways in the GCC and Egypt are shaped by institutional rules that do not appear in global data: NUPCO tender cycles in Saudi public hospitals, DHA and DOH formulary decisions in the UAE, UPA procurement and EDA registration in Egypt, and the role of hospital pharmacy committees in all three. Interviews with the people inside those processes reveal the real adoption barriers before a brand plan is written.',
        'Physician decision-making is also more relationship-driven than in many Western markets. Key opinion leaders, department heads and visiting consultants carry outsized influence over protocol adoption. Mapping who influences whom, and what evidence each finds persuasive, is a qualitative task.',
        'Patient journeys differ by sector and nationality. Expatriate and national populations in the Gulf move through different insurance and provider systems; in Egypt, out-of-pocket spending and pharmacy-led care change where interventions can land. Ethnographic and patient-interview work surfaces these differences so programmes are designed for the pathway that exists.',
        'Qualitative research also protects quantitative budgets. A 20-interview phase that reveals the vocabulary, segments and objections that matter makes the survey that follows shorter, more precise and more defensible to global teams.',
      ],
    },
    approach: {
      heading: 'How a BioNixus qualitative programme runs',
      intro: 'A 20–30 interview single-country study typically reports in five to seven weeks; multi-country programmes run in parallel.',
      steps: [
        {
          title: '1. Scoping call and hypothesis map',
          body: 'The scoping call lists what the team believes and what it needs to learn. Hypotheses become the spine of the discussion guide and the analysis framework, so the read-out answers the original question.',
        },
        {
          title: '2. Recruitment through hospital and payer networks',
          body: 'KOLs, specialists, pharmacists, procurement and payer stakeholders are recruited through BioNixus relationships with public and private hospital groups and health authorities, with screening on influence, caseload and decision role.',
        },
        {
          title: '3. Guide design and transcreation',
          body: 'Discussion guides are drafted with the client, reviewed by medical advisors, and transcreated into Arabic or local languages so probes land naturally. Stimulus, including value stories and detail aids, is adapted for local regulatory codes.',
        },
        {
          title: '4. Moderation and analysis',
          body: 'Interviews run face to face, by video or in clinic and are moderated by senior researchers. Transcripts are coded against the hypothesis framework; disconfirming evidence is reported, not smoothed.',
        },
        {
          title: '5. Read-out and next step',
          body: 'Findings are delivered as decision implications with verbatims, influence maps or journey maps, and a recommendation on what to validate quantitatively or change immediately.',
        },
      ],
    },
    useCases: {
      heading: 'Where qualitative research earns its budget',
      items: [
        { title: 'KOL and expert interviews', body: 'Clinical perspective on unmet need, treatment sequencing and evidence expectations ahead of launch or label extension.' },
        { title: 'Payer and procurement interviews', body: 'How SFDA, NUPCO, MOHAP, DHA, DOH, EDA and hospital committee stakeholders weigh evidence, price and budget impact.' },
        { title: 'Patient journey mapping', body: 'Diagnosis-to-treatment pathways by sector and population, with the drop-off points where support programmes change outcomes.' },
        { title: 'Advisory boards', body: 'Structured expert panels that pressure-test strategy, protocols or value messages with clinical and policy voices.' },
        { title: 'Message and value-story development', body: 'Exploratory testing of positioning, claims and detail aids before quantitative validation.' },
        { title: 'Pharmacist and channel research', body: 'Dispensing behaviour, substitution and stock decisions in retail and hospital pharmacy across the GCC and Egypt.' },
      ],
    },
    compare: {
      heading: 'Qualitative research vs desk research and syndicated reports',
      intro: 'Desk research and syndicated reports describe the market; qualitative research explains the people in it.',
      rows: [
        { dimension: 'Source', syndicated: 'Published data, past sales, analyst opinion', bionixus: 'Direct interviews with prescribers, payers, pharmacists and patients' },
        { dimension: 'Depth', syndicated: 'Aggregate and retrospective', bionixus: 'Motivations, objections and decision rules, in the stakeholder\u2019s words' },
        { dimension: 'Local realism', syndicated: 'Regional averages', bionixus: 'Country- and institution-specific pathways, bilingual verbatims' },
        { dimension: 'Output', syndicated: 'Report', bionixus: 'Frameworks, maps and hypotheses ready for action or quantitative testing' },
        { dimension: 'Ownership', syndicated: 'Shared or licensed', bionixus: 'Client-owned transcripts, recordings and analysis' },
      ],
    },
    scope: {
      heading: 'Scope, timelines and pricing',
      paragraphs: [
        PRICING_PARA,
        'A 20–30 interview single-country programme usually reports in five to seven weeks. Multi-country work runs in parallel with one analysis framework. ' + FOOTPRINT,
      ],
    },
    related: {
      heading: 'Related BioNixus pages',
      links: [
        { to: '/healthcare-market-research', label: 'Healthcare market research hub: markets, methods and who to brief' },
        { to: '/services/kol-stakeholder-mapping', label: 'KOL mapping and stakeholder engagement research' },
        { to: '/services/quantitative-research', label: 'Quantitative healthcare research and physician surveys' },
        { to: '/healthcare-market-research/saudi-arabia', label: 'Healthcare market research in Saudi Arabia' },
        { to: '/pricing', label: 'Published pricing bands for primary research' },
      ],
    },
    faqs: [
      {
        question: 'How many interviews does a qualitative study need?',
        answer:
          'Most single-country studies reach thematic saturation at 15–25 interviews per stakeholder group. Multi-stakeholder programmes (physicians plus payers plus pharmacists) are sized per group. BioNixus recommends the count during the scoping call based on the number of hypotheses and segments.',
      },
      {
        question: 'Can you recruit KOLs and payers in Saudi Arabia and the UAE?',
        answer:
          'Yes. BioNixus recruits through its relationships with public and private hospital groups, health authorities and professional societies rather than open panels, and screens on influence, caseload and decision role. Recruitment of payer and procurement stakeholders is scoped realistically in the proposal.',
      },
      {
        question: 'Are interviews conducted in Arabic?',
        answer:
          'Interviews run in the respondent\u2019s preferred language, Arabic, English or a mix, with native-speaking senior moderators. Guides are transcreated, and verbatims are delivered in the original language alongside English.',
      },
      {
        question: 'How do you avoid bias when the client has a hypothesis?',
        answer:
          'Hypotheses are written down before fieldwork and the analysis framework records supporting and disconfirming evidence for each. Moderators use neutral probes and stimulus is rotated. The read-out reports where the evidence contradicts expectations.',
      },
      {
        question: 'Should we run qualitative research before a survey?',
        answer:
          'Usually yes when the category, segments or vocabulary are not yet understood. A short qualitative phase makes the survey shorter and more precise. When the question is already well framed, BioNixus may recommend moving straight to quantitative work.',
      },
      {
        question: 'What does a qualitative programme cost?',
        answer:
          'Qualitative programmes sit toward the lower half of the published $10,000–$60,000 band depending on stakeholder seniority, number of countries and languages. A costed proposal follows the scoping call within 48 hours.',
      },
    ],
  },

  'market-access': {
    defaultNeed: 'Market access',
    ctaHeadline: 'Preparing an SFDA, NUPCO, MOHAP or HTA submission?',
    answer: {
      question: 'What do market access services for pharmaceutical companies include?',
      answer:
        'Market access services help a pharmaceutical or medtech company get a product listed, priced, reimbursed and procured in a target market. In practice that means payer and procurement research, pricing and reimbursement strategy, health-economic evidence (budget-impact and cost-effectiveness models), value dossiers and tender strategy. BioNixus provides market access consulting for the GCC, Egypt and Turkey, where it has in-house teams, and for the UK and EU5 HTA systems (NICE, G-BA, HAS, AIFA, AEMPS), combining primary payer research with evidence development.',
      points: [
        { title: 'GCC regulatory and procurement reality', description: 'SFDA registration and Economic Evaluation System requirements, NUPCO tenders, MOHAP, DHA and DOH listing, MOH Kuwait and MOPH Qatar formularies.' },
        { title: 'Primary payer research', description: 'Interviews and surveys with payer advisors, procurement heads, P&T committee members and hospital pharmacists, not desk assumptions.' },
        { title: 'Health-economic evidence', description: 'Budget-impact and cost-effectiveness models with local inputs, HTA dossier preparation and value-story development.' },
        { title: 'Tender and formulary strategy', description: 'Mapping of tender cycles, award criteria and formulary decision points so launch sequencing matches procurement reality.' },
      ],
      summary: 'BioNixus is the regional alternative to global access consultancies: faster, bilingual and present in the committees that decide.',
    },
    whyNow: {
      heading: 'Why market access decides GCC and EMEA launches',
      paragraphs: [
        'Saudi Arabia has moved from price referencing to formal economic evaluation. The SFDA Economic Evaluation System, mandatory since 1 July 2025, expects pharmacoeconomic and budget-impact submissions at registration, and NUPCO consolidates public-sector purchasing into tenders whose criteria and cycles determine volume. A product can be registered and still miss the volume that justifies the launch.',
        'The UAE decides emirate by emirate. MOHAP, DHA and DOH each run listing processes, and the private insurance sector, including mandatory schemes, adds payer logic of its own. Kuwait and Qatar run centralised ministry formularies. Treating the Gulf as one access market is the most common and most expensive error.',
        'Egypt combines EDA registration with UPA public procurement and a large out-of-pocket private market, so pricing and reimbursement strategy must cover three channels at once. Turkey\u2019s SGK reimbursement list and reference-pricing regime demand a separate evidence approach.',
        'UK and EU5 HTA bodies continue to raise evidence expectations, and global dossiers rarely transfer unchanged to Gulf regulators. Teams need an access partner that understands both systems and can generate local evidence, through payer research and economic modelling, that each committee finds credible.',
      ],
    },
    approach: {
      heading: 'How a BioNixus market access programme runs',
      intro: 'Access programmes are modular; most start with landscape and payer research and add economic modelling as the submission approaches.',
      steps: [
        { title: '1. Scoping call and access map', body: 'The call fixes the target markets, launch timeline and decision points: registration, listing, tender, reimbursement. Each becomes a workstream with an evidence requirement and a stakeholder list.' },
        { title: '2. Landscape and precedent analysis', body: 'Review of comparator listings, tender awards, price corridors and HTA precedents in each market, including SFDA EES requirements, NUPCO award histories and HTA appraisals in the UK and EU5.' },
        { title: '3. Primary payer and procurement research', body: 'Interviews and, where needed, surveys with payer advisors, procurement heads, P&T committee members and hospital pharmacists to test value messages, price corridors and evidence expectations.' },
        { title: '4. Evidence development', body: 'Budget-impact and cost-effectiveness models built with local epidemiology, treatment patterns and cost inputs; value dossiers and objection handlers aligned to each committee\u2019s format.' },
        { title: '5. Strategy, sequencing and support', body: 'A market-by-market access plan with launch sequencing, tender calendar, price corridor and negotiation materials, plus support through submissions and committee questions.' },
      ],
    },
    useCases: {
      heading: 'Market access questions BioNixus answers',
      items: [
        { title: 'SFDA EES submission support', body: 'Budget-impact and cost-effectiveness inputs structured for the Saudi Economic Evaluation System, with local data sourcing.' },
        { title: 'NUPCO and hospital tender strategy', body: 'Tender cycle mapping, award-criteria analysis and bid-price research for Saudi public hospitals and other GCC centralised buyers.' },
        { title: 'UAE emirate listing', body: 'MOHAP, DHA and DOH formulary strategy and private-insurer coverage research for national and expatriate populations.' },
        { title: 'Pricing and reimbursement corridors', body: 'Payer willingness-to-pay and reference-price analysis across GCC, Egypt, Turkey and EU5.' },
        { title: 'HTA dossier and value story', body: 'Evidence gap analysis and dossier preparation for NICE, G-BA, HAS, AIFA and AEMPS, adapted for Gulf regulators.' },
        { title: 'Launch sequencing', body: 'Which market first, which channel first, and what evidence must exist before each committee date.' },
      ],
    },
    compare: {
      heading: 'BioNixus market access consulting vs global access consultancies',
      intro: 'Global firms bring scale; BioNixus brings presence in the Gulf and Egyptian committees and primary research in the same engagement.',
      rows: [
        { dimension: 'Regional presence', syndicated: 'Hub offices, local sub-contracting', bionixus: 'In-house teams in Saudi Arabia, UAE, Egypt and the UK' },
        { dimension: 'Evidence source', syndicated: 'Desk research and global precedents', bionixus: 'Primary payer and procurement research plus local modelling inputs' },
        { dimension: 'Language', syndicated: 'English, translated outputs', bionixus: 'Arabic–English working teams and bilingual dossiers' },
        { dimension: 'Speed', syndicated: 'Quarter-long engagements', bionixus: 'Scoped modules reporting in weeks' },
        { dimension: 'Pricing', syndicated: 'Retainer-led', bionixus: 'Project-priced within the published $10,000–$60,000 band per module' },
      ],
    },
    scope: {
      heading: 'Scope, timelines and pricing',
      paragraphs: [
        PRICING_PARA,
        'Payer research modules report in six to eight weeks; economic models and dossiers are scheduled to committee dates. ' + FOOTPRINT,
      ],
    },
    related: {
      heading: 'Related BioNixus pages',
      links: [
        { to: '/heor-consulting', label: 'HEOR consulting: budget impact, cost-effectiveness and RWE' },
        { to: '/gcc-market-access-guide', label: 'GCC market access guide: SFDA, NUPCO, MOHAP, DHA and DOH' },
        { to: '/saudi-payer-market-access-research', label: 'Saudi payer market access research' },
        { to: '/healthcare-market-research', label: 'Healthcare market research hub: markets, methods and who to brief' },
        { to: '/pricing', label: 'Published pricing bands for primary research' },
      ],
    },
    faqs: [
      {
        question: 'What does the SFDA Economic Evaluation System require?',
        answer:
          'Since 1 July 2025 the SFDA expects pharmacoeconomic evidence, typically budget-impact and cost-effectiveness analyses with Saudi inputs, as part of registration for in-scope products. BioNixus builds those models with local epidemiology, treatment-pattern and cost data and structures them to the SFDA format.',
      },
      {
        question: 'How do NUPCO tenders affect launch volume?',
        answer:
          'NUPCO consolidates purchasing for Saudi public hospitals, so tender inclusion and award price determine most public-sector volume. BioNixus maps tender cycles and award criteria, researches bid-price expectations and advises on sequencing so registration, listing and tender timing align.',
      },
      {
        question: 'Can one dossier serve the whole GCC?',
        answer:
          'No. Saudi Arabia, the UAE emirates, Kuwait and Qatar run separate listing and procurement processes with different evidence expectations. BioNixus builds a core value story and adapts the evidence package, price corridor and submission format for each authority.',
      },
      {
        question: 'Do you support UK and European HTA submissions?',
        answer:
          'Yes. BioNixus supports evidence gap analysis, payer research and dossier preparation for NICE, G-BA/IQWiG, HAS/CEPS, AIFA and AEMPS, and helps adapt global dossiers for Gulf and Egyptian regulators.',
      },
      {
        question: 'Do you interview actual payers and procurement decision-makers?',
        answer:
          'Yes. BioNixus recruits payer advisors, procurement heads, pharmacy and therapeutics committee members and hospital pharmacists through its hospital and health-authority relationships, and reports realistic recruitment expectations per market in the proposal.',
      },
      {
        question: 'What does a market access programme cost and how long does it take?',
        answer:
          'Modules are priced within the published $10,000–$60,000 band; payer research reports in six to eight weeks and models and dossiers are scheduled to committee dates. A costed proposal follows the scoping call within 48 hours.',
      },
    ],
  },

  'competitive-intelligence': {
    defaultNeed: 'Brand and competitor data (account- or SKU-level)',
    ctaHeadline: 'Need competitor and account-level intelligence before launch?',
    answer: {
      question: 'What is pharmaceutical competitive intelligence and how is it gathered ethically?',
      answer:
        'Pharmaceutical competitive intelligence is the systematic, legal collection and analysis of information about competitor products, pipelines, pricing, access status and field activity, turned into decisions for launch, lifecycle and defence. It is gathered from public sources (registries, tender awards, regulatory databases, conference disclosures), from syndicated data, and above all from primary research with the physicians, pharmacists and procurement stakeholders who see competitors every day. BioNixus delivers competitive intelligence for pharma and medtech across the GCC, Egypt, Turkey, the UK, EU5 and selected Asian markets, with account-level breakdowns by hospital group and pharmacy chain.',
      points: [
        { title: 'Primary-research led', description: 'Physician, pharmacist and procurement interviews and surveys reveal competitor messaging, perceived strengths and switching triggers.' },
        { title: 'Account-level resolution', description: 'Share, formulary status and detailing intensity reported by hospital group, pharmacy chain and insurer, not just national totals.' },
        { title: 'Regulatory and tender monitoring', description: 'SFDA, EDA, MOHAP, NUPCO and European registries tracked for approvals, listings and awards that signal competitor moves.' },
        { title: 'Compliant by design', description: 'Methods follow EphMRA and ESOMAR codes; no misrepresentation, no confidential-information solicitation.' },
      ],
      summary: 'BioNixus competitive intelligence is the primary-research complement to syndicated audits: the audit shows the share, the intelligence explains how the competitor won it.',
    },
    whyNow: {
      heading: 'Why competitive intelligence has become account-level',
      paragraphs: [
        'National share tells a brand team that it is losing; it does not say where or why. In GCC and Egyptian markets, a handful of hospital groups, pharmacy chains and insurers decide most volume, so competitive position must be read account by account: which formulary lists the competitor, which tender it won, which pharmacy chain stocks it preferentially, and what its representatives are saying in those accounts.',
        'Biosimilar and generic entry compresses response time. When a competitor wins a NUPCO award or a DHA listing, the originator has one cycle to respond. Teams that monitor regulatory and tender signals and run quick physician pulses can adjust messaging, pricing and field priorities before the next cycle rather than after the audit confirms the loss.',
        'Competitor messaging is only visible through the people who hear it. Physician and pharmacist interviews reveal which claims are landing, which objections competitors are seeding against your brand, and which key opinion leaders they have engaged. This is the layer no database provides.',
        'Finally, global pipeline intelligence rarely reflects regional timing. A product approved in Europe may be years from Gulf registration or may be fast-tracked; local regulatory tracking and payer interviews turn global pipeline data into a regional launch calendar.',
      ],
    },
    approach: {
      heading: 'How a BioNixus competitive intelligence programme runs',
      intro: 'Programmes run as one-off landscape assessments or as quarterly monitoring with physician pulses.',
      steps: [
        { title: '1. Scoping call and intelligence questions', body: 'The call defines the competitor set, the markets and accounts that matter, and the decisions the intelligence must inform: launch sequencing, pricing response, field deployment or defence planning.' },
        { title: '2. Secondary and regulatory baseline', body: 'Registries, tender awards, formulary lists, conference disclosures and syndicated data are compiled into a baseline of competitor status by market and account.' },
        { title: '3. Primary research with the field', body: 'Interviews and surveys with physicians, hospital and retail pharmacists and procurement stakeholders capture competitor messaging, perceived differentiation, switching triggers and detailing intensity by account.' },
        { title: '4. Analysis and war-gaming', body: 'Findings are synthesised into competitor profiles, SWOT and scenario analyses; where useful, BioNixus facilitates war-game workshops with brand, medical and access teams to test responses.' },
        { title: '5. Read-out and monitoring cadence', body: 'A decision-ready report with account-level tables and a recommended response plan, followed, if commissioned, by quarterly monitoring with alerts on regulatory, tender and field changes.' },
      ],
    },
    useCases: {
      heading: 'Competitive intelligence questions BioNixus answers',
      items: [
        { title: 'Launch readiness and landscape', body: 'Competitor positioning, access status and expected response by market before a launch date is fixed.' },
        { title: 'Biosimilar and generic entry impact', body: 'Switching intent, substitution rules and tender exposure by account when exclusivity ends.' },
        { title: 'Account-level share and formulary mapping', body: 'Which hospital groups, pharmacy chains and insurers list, stock and prefer each brand.' },
        { title: 'Competitor messaging and KOL engagement', body: 'What physicians hear from competitor representatives and which experts competitors have engaged.' },
        { title: 'Pricing and tender response', body: 'Competitor bid behaviour and price corridors from tender histories and procurement interviews.' },
        { title: 'Pipeline and regulatory tracking', body: 'Regional approval, listing and award signals that convert global pipeline data into a local calendar.' },
      ],
    },
    compare: {
      heading: 'Primary competitive intelligence vs syndicated audit and pipeline data',
      intro: 'Syndicated data is the starting point; primary intelligence explains and anticipates it.',
      rows: [
        { dimension: 'What it shows', syndicated: 'Historical share and pipeline status', bionixus: 'How competitors win accounts and what they will do next' },
        { dimension: 'Resolution', syndicated: 'National or channel totals', bionixus: 'Hospital group, pharmacy chain, insurer' },
        { dimension: 'Competitor messaging', syndicated: 'Not captured', bionixus: 'Reported by the physicians and pharmacists who hear it' },
        { dimension: 'Regional timing', syndicated: 'Global pipeline dates', bionixus: 'SFDA, EDA, MOHAP, NUPCO and HTA signals tracked locally' },
        { dimension: 'Compliance', syndicated: 'Licensed data', bionixus: 'Primary research under EphMRA and ESOMAR codes; client-owned' },
      ],
    },
    scope: {
      heading: 'Scope, timelines and pricing',
      paragraphs: [
        PRICING_PARA,
        'Landscape assessments report in six to eight weeks; monitoring programmes run quarterly with physician pulses. ' + FOOTPRINT,
      ],
    },
    related: {
      heading: 'Related BioNixus pages',
      links: [
        { to: '/healthcare-market-research', label: 'Healthcare market research hub: markets, methods and who to brief' },
        { to: '/services/quantitative-research', label: 'Quantitative physician surveys for ATU and share tracking' },
        { to: '/pharmaceutical-companies-saudi-arabia', label: 'Pharmaceutical companies in Saudi Arabia: 2026 directory' },
        { to: '/iqvia-alternative', label: 'IQVIA alternatives and competitors compared for pharma' },
        { to: '/pricing', label: 'Published pricing bands for primary research' },
      ],
    },
    faqs: [
      {
        question: 'Is pharmaceutical competitive intelligence legal and compliant?',
        answer:
          'Yes when it is gathered from public sources, licensed data and properly consented primary research. BioNixus follows EphMRA and ESOMAR codes: respondents know they are taking part in market research, no one is asked to disclose confidential employer information, and no misrepresentation is used.',
      },
      {
        question: 'How is competitive intelligence different from syndicated audit data?',
        answer:
          'Audit data reports historical sales by pack and channel. Competitive intelligence explains how competitors won those sales, what they are saying in accounts, and what regulatory, tender and pipeline signals indicate about their next move. BioNixus typically pairs both.',
      },
      {
        question: 'Can you report competitor position by hospital group or pharmacy chain?',
        answer:
          'Yes. Account-level breakdowns by hospital group, pharmacy chain and insurer are a BioNixus specialism in the GCC and Egypt, built from procurement and pharmacist interviews, formulary and tender records and physician surveys.',
      },
      {
        question: 'Do you track competitor pipelines and regulatory filings in the Gulf?',
        answer:
          'BioNixus monitors SFDA, EDA, MOHAP and other regional registries, NUPCO and hospital tender awards, and HTA decisions in the UK and EU5, and converts global pipeline data into a regional launch calendar.',
      },
      {
        question: 'Can competitive intelligence be run as an ongoing service?',
        answer:
          'Yes. Quarterly monitoring combines regulatory and tender alerts with short physician and pharmacist pulses so brand teams see competitor moves within the cycle rather than after the audit.',
      },
      {
        question: 'What does a competitive intelligence programme cost?',
        answer:
          'One-off landscape assessments and quarterly monitoring are priced within the published $10,000–$60,000 band depending on markets, competitor set and primary-research depth. A costed proposal follows the scoping call within 48 hours.',
      },
    ],
  },

  'clinical-trial-support': {
    defaultNeed: 'Primary market research',
    ctaHeadline: 'Planning a feasibility, site or patient-recruitment study?',
    answer: {
      question: 'How does market research support clinical trial planning in the GCC and EMEA?',
      answer:
        'Clinical trial support research answers the commercial and operational questions a protocol cannot: which countries and sites can recruit the target patients, how investigators and patients view the design, what competing trials are drawing from the same pool, and how the evidence package should be shaped for the payers who will later judge it. BioNixus runs investigator and site feasibility interviews, patient-pathway and recruitment research, protocol acceptability testing and payer-evidence planning across Saudi Arabia, the UAE, Egypt, Turkey, the UK, EU5 and selected Asian markets. It does not run clinical trials; it provides the primary research that makes them recruit and pay off.',
      points: [
        { title: 'Investigator and site feasibility', description: 'Interviews with principal investigators, study coordinators and hospital research offices on patient access, competing studies and approval timelines.' },
        { title: 'Patient recruitment research', description: 'Pathway mapping and patient interviews to locate where eligible patients are managed and what would make them enrol.' },
        { title: 'Protocol and endpoint acceptability', description: 'Clinician and payer feedback on design, comparators and endpoints before the protocol locks.' },
        { title: 'Evidence-to-access planning', description: 'Alignment of trial outputs with SFDA EES, NUPCO, MOHAP, NICE and other payer evidence expectations.' },
      ],
      summary: 'BioNixus is a research partner to clinical operations and medical affairs, not a CRO: feasibility, acceptability and access evidence delivered in weeks.',
    },
    whyNow: {
      heading: 'Why Gulf and Egyptian trials need local feasibility research',
      paragraphs: [
        'Saudi Arabia, the UAE and Egypt are investing in clinical research capacity, and sponsors are moving trials into the region for treatment-naive populations and fast enrolment. But site capability, ethics approval timelines and research-office processes differ sharply between institutions. Feasibility built on registry counts alone frequently overestimates recruitment.',
        'Approvals stack rather than run in parallel. SFDA and national ethics committee clearance in Saudi Arabia, DOH and DHA research approvals in the UAE, and EDA and institutional review in Egypt each add weeks that global timelines rarely include. Interviewing research offices before site selection avoids the mid-study stall.',
        'Patient pathways determine where eligible patients can actually be found. Expatriate and national populations in the Gulf move through different insurers and providers; in Egypt, pharmacy-led and out-of-pocket care means many patients are not in hospital records. Pathway research tells recruitment teams which doors to knock on.',
        'The access file starts at protocol design. Payers in the Gulf and Europe increasingly ask for comparators, endpoints and local sub-populations that a global protocol may omit. Testing the design with payer advisors and local clinicians before lock protects the launch that the trial is meant to enable.',
      ],
    },
    approach: {
      heading: 'How a BioNixus clinical trial support study runs',
      intro: 'Feasibility and acceptability studies report in four to eight weeks, ahead of site selection or protocol lock.',
      steps: [
        { title: '1. Scoping call and operational questions', body: 'The call defines the indication, target population, candidate countries and the decisions the research must inform: country and site selection, protocol adjustments or recruitment planning.' },
        { title: '2. Site and investigator mapping', body: 'Candidate centres are mapped by caseload, research infrastructure, past study performance and approval pathway using registries, publications and BioNixus hospital relationships.' },
        { title: '3. Investigator, coordinator and research-office interviews', body: 'Structured interviews cover patient access, competing trials, staffing, ethics and regulatory timelines and willingness to participate, recorded against a feasibility scorecard.' },
        { title: '4. Patient pathway and acceptability research', body: 'Patient and clinician interviews locate eligible patients in the care pathway and test protocol burden, visit schedules and consent materials; payer advisors review comparators and endpoints.' },
        { title: '5. Feasibility read-out and access alignment', body: 'A ranked country and site shortlist with realistic recruitment curves, approval timelines, protocol recommendations and an evidence plan aligned to the payers who will judge the results.' },
      ],
    },
    useCases: {
      heading: 'Clinical trial questions BioNixus answers',
      items: [
        { title: 'Country and site feasibility', body: 'Which GCC, Egyptian, Turkish and European centres can recruit the protocol population and how fast.' },
        { title: 'Investigator sentiment and competing studies', body: 'Interest, capacity and the trials already drawing from the same patients.' },
        { title: 'Patient recruitment and retention', body: 'Where eligible patients are managed, what motivates enrolment and what drives drop-out.' },
        { title: 'Protocol and endpoint acceptability', body: 'Clinician and payer feedback on comparators, endpoints, visit burden and local sub-populations.' },
        { title: 'Approval timeline mapping', body: 'Ethics, regulatory and institutional steps by country and institution so timelines reflect reality.' },
        { title: 'Evidence-to-access planning', body: 'Making trial outputs usable for SFDA EES, NUPCO, MOHAP and HTA submissions.' },
      ],
    },
    compare: {
      heading: 'BioNixus clinical trial support vs CRO feasibility questionnaires',
      intro: 'CRO feasibility surveys collect site self-reports; BioNixus research tests them.',
      rows: [
        { dimension: 'Method', syndicated: 'Emailed site questionnaires', bionixus: 'Structured interviews with investigators, coordinators, research offices and patients' },
        { dimension: 'Recruitment estimate', syndicated: 'Site self-reported counts', bionixus: 'Pathway-validated estimates with competing-study adjustment' },
        { dimension: 'Approval timelines', syndicated: 'Generic country averages', bionixus: 'Institution-specific ethics and regulatory steps' },
        { dimension: 'Access alignment', syndicated: 'Out of scope', bionixus: 'Payer review of comparators and endpoints before lock' },
        { dimension: 'Role', syndicated: 'Trial execution', bionixus: 'Independent primary research supporting sponsor and CRO decisions' },
      ],
    },
    scope: {
      heading: 'Scope, timelines and pricing',
      paragraphs: [
        PRICING_PARA,
        'Feasibility and acceptability studies report in four to eight weeks, scheduled ahead of site selection or protocol lock. ' + FOOTPRINT,
      ],
    },
    related: {
      heading: 'Related BioNixus pages',
      links: [
        { to: '/healthcare-market-research', label: 'Healthcare market research hub: markets, methods and who to brief' },
        { to: '/services/market-access', label: 'Market access consulting for SFDA, NUPCO and HTA submissions' },
        { to: '/heor-consulting', label: 'HEOR consulting: budget impact, cost-effectiveness and RWE' },
        { to: '/hospital-groups-saudi-arabia', label: 'Hospital groups in Saudi Arabia: 2026 directory' },
        { to: '/pricing', label: 'Published pricing bands for primary research' },
      ],
    },
    faqs: [
      {
        question: 'Does BioNixus run clinical trials?',
        answer:
          'No. BioNixus is a primary research firm. It provides feasibility, investigator, patient-pathway, protocol-acceptability and evidence-planning research that sponsors and CROs use to select sites, adjust protocols and plan recruitment.',
      },
      {
        question: 'Which countries do you cover for trial feasibility?',
        answer:
          'In-house coverage of Saudi Arabia, the UAE, Egypt and the UK, with established partners in Turkey, EU5 and selected Asian and Latin American markets. Country scope is confirmed in the scoping call.',
      },
      {
        question: 'How do you estimate recruitment more reliably than site questionnaires?',
        answer:
          'By interviewing investigators and coordinators rather than emailing forms, mapping where eligible patients are actually managed, and adjusting for competing studies and approval timelines. Estimates are reported as ranges with the assumptions stated.',
      },
      {
        question: 'Can you test a protocol with payers before it is finalised?',
        answer:
          'Yes. Payer advisors and local clinicians review comparators, endpoints and sub-populations so the trial generates evidence that SFDA, NUPCO, MOHAP, NICE and other bodies will accept later.',
      },
      {
        question: 'How long does a feasibility study take?',
        answer:
          'Four to eight weeks depending on the number of countries and stakeholder groups, scheduled ahead of site selection or protocol lock.',
      },
      {
        question: 'What does clinical trial support research cost?',
        answer:
          'Studies are priced within the published $10,000–$60,000 band depending on countries, stakeholder groups and depth. A costed proposal follows the scoping call within 48 hours.',
      },
    ],
  },

  'kol-stakeholder-mapping': {
    defaultNeed: 'Primary market research',
    ctaHeadline: 'Need a KOL map or stakeholder plan for a priority market?',
    answer: {
      question: 'What is KOL mapping and how does it work in the GCC and EMEA?',
      answer:
        'KOL mapping identifies the clinicians, researchers, pharmacists, payers and policy figures who influence how a therapy is adopted in a market, measures their influence and reach, and records what evidence and engagement each responds to. It combines publication, guideline and conference analysis with primary interviews among peers who name the people they actually follow. BioNixus maps key opinion leaders and stakeholders for pharma and medtech across Saudi Arabia, the UAE, Egypt, Turkey, the UK, EU5 and selected Asian markets, bilingual in Arabic and English, and turns the map into an engagement plan for medical affairs.',
      points: [
        { title: 'Peer-nominated influence', description: 'Physician interviews reveal the department heads, visiting consultants and society figures peers defer to, not just the most published.' },
        { title: 'Institutional stakeholders', description: 'Hospital pharmacists, P&T committee members, procurement heads and payer advisors mapped alongside clinical KOLs.' },
        { title: 'Evidence preferences', description: 'What each stakeholder finds persuasive, local data, global trials, health-economic arguments, so engagement is relevant.' },
        { title: 'Engagement plan', description: 'Tiered plans with roles for medical science liaisons, advisory boards and congress activity, compliant with local codes.' },
      ],
      summary: 'BioNixus KOL mapping is built for medical affairs teams who need to know who decides protocol in each Gulf and Egyptian institution, not just who publishes.',
    },
    whyNow: {
      heading: 'Why stakeholder mapping matters more in relationship-driven markets',
      paragraphs: [
        'Protocol adoption in Gulf and Egyptian hospitals often follows a department head or a visiting consultant rather than a national guideline. The most-cited author in a therapy area may have little influence in the institutions that carry the volume. Peer-nominated mapping finds the people who actually shift practice.',
        'Influence extends beyond clinicians. Hospital pharmacists, pharmacy and therapeutics committees, procurement heads and payer advisors decide whether a therapy is available at all. A KOL map that stops at physicians leaves the access decision unmapped.',
        'Medical affairs teams are also under tighter compliance expectations. Engagement plans must document why a stakeholder was selected, what the scientific exchange is for and how it complies with local promotional codes. A documented, research-based map is the foundation of a defensible plan.',
        'Stakeholder landscapes change quickly as new hospitals open, consultants relocate between Gulf countries and health systems reorganise. Mapping that is refreshed before each planning cycle keeps engagement aimed at current influence rather than last year\u2019s.',
      ],
    },
    approach: {
      heading: 'How a BioNixus KOL and stakeholder mapping study runs',
      intro: 'A single-country, single-indication map typically reports in six to eight weeks.',
      steps: [
        { title: '1. Scoping call and influence questions', body: 'The call fixes the indication, markets, stakeholder types and the engagement decisions the map must support: advisory board composition, MSL territory design, congress planning or access engagement.' },
        { title: '2. Desk mapping', body: 'Publication, guideline authorship, trial leadership, society roles and conference activity are compiled into a long list of candidate influencers by country and institution.' },
        { title: '3. Peer-nomination interviews', body: 'Structured interviews with practising specialists, pharmacists and committee members ask who they consult, follow and defer to, producing influence scores that desk data cannot.' },
        { title: '4. Stakeholder profiling', body: 'Shortlisted KOLs and institutional stakeholders are profiled on reach, influence domain, evidence preferences, current affiliations and engagement history where known.' },
        { title: '5. Engagement plan and read-out', body: 'A tiered map with recommended roles, scientific-exchange themes and a compliant engagement calendar, delivered with the underlying data for CRM upload.' },
      ],
    },
    useCases: {
      heading: 'How medical affairs teams use BioNixus mapping',
      items: [
        { title: 'Pre-launch KOL identification', body: 'Who shapes protocol in the target indication in each market and institution before medical teams are deployed.' },
        { title: 'Advisory board composition', body: 'Balanced panels across institutions, sectors and influence domains with documented selection rationale.' },
        { title: 'MSL territory and priority design', body: 'Stakeholder tiers by geography and institution to allocate medical science liaison time.' },
        { title: 'Access stakeholder mapping', body: 'Pharmacy, P&T, procurement and payer influencers who decide listing and tender outcomes.' },
        { title: 'Congress and society planning', body: 'Which regional and national meetings and societies carry influence for the indication.' },
        { title: 'Map refresh', body: 'Annual or pre-cycle updates as consultants move and institutions reorganise.' },
      ],
    },
    compare: {
      heading: 'Peer-nominated mapping vs publication-only KOL databases',
      intro: 'Databases find the published; interviews find the followed.',
      rows: [
        { dimension: 'Influence measure', syndicated: 'Citations, trial roles, society titles', bionixus: 'Peer nomination plus desk indicators' },
        { dimension: 'Institutional stakeholders', syndicated: 'Rarely covered', bionixus: 'Pharmacists, committees, procurement and payers included' },
        { dimension: 'Local realism', syndicated: 'Global databases, thin Gulf and Egypt coverage', bionixus: 'In-country interviews in Arabic and English' },
        { dimension: 'Evidence preferences', syndicated: 'Not captured', bionixus: 'Recorded per stakeholder for relevant scientific exchange' },
        { dimension: 'Output', syndicated: 'List', bionixus: 'Tiered map, engagement plan and CRM-ready data' },
      ],
    },
    scope: {
      heading: 'Scope, timelines and pricing',
      paragraphs: [
        PRICING_PARA,
        'Single-country, single-indication maps report in six to eight weeks; multi-country programmes run in parallel. ' + FOOTPRINT,
      ],
    },
    related: {
      heading: 'Related BioNixus pages',
      links: [
        { to: '/healthcare-market-research', label: 'Healthcare market research hub: markets, methods and who to brief' },
        { to: '/services/qualitative-research', label: 'Qualitative pharma research: KOL interviews and advisory boards' },
        { to: '/healthcare-market-research/services/kol-mapping', label: 'KOL mapping as part of a country research programme' },
        { to: '/hospital-groups-uae', label: 'Hospital groups in the UAE: 2026 directory' },
        { to: '/pricing', label: 'Published pricing bands for primary research' },
      ],
    },
    faqs: [
      {
        question: 'How is peer-nominated KOL mapping different from a publication database?',
        answer:
          'Databases rank by citations, trial roles and titles. Peer nomination asks practising specialists who they consult and follow, which surfaces department heads and visiting consultants who shape protocol without publishing widely. BioNixus combines both.',
      },
      {
        question: 'Do you map stakeholders beyond physicians?',
        answer:
          'Yes. Hospital pharmacists, pharmacy and therapeutics committee members, procurement heads, payer advisors and policy figures are profiled alongside clinical KOLs because they decide availability.',
      },
      {
        question: 'Which markets do you cover for KOL mapping?',
        answer:
          'In-house coverage of Saudi Arabia, the UAE, Egypt and the UK, with partners in Turkey, EU5 and selected Asian markets. Gulf and Egyptian interviews are conducted in Arabic or English by senior researchers.',
      },
      {
        question: 'Is the output compatible with our CRM or medical affairs platform?',
        answer:
          'Yes. The tiered map is delivered as a structured dataset with stakeholder profiles, influence scores and engagement recommendations ready for CRM upload, alongside the narrative read-out.',
      },
      {
        question: 'How do you keep the engagement plan compliant?',
        answer:
          'Selection rationale, scientific-exchange purpose and tiering are documented for each stakeholder, and recommendations follow local promotional and transparency codes so medical affairs can defend the plan.',
      },
      {
        question: 'How long does KOL mapping take and what does it cost?',
        answer:
          'Single-country maps report in six to eight weeks and are priced within the published $10,000–$60,000 band depending on markets and stakeholder groups. A costed proposal follows the scoping call within 48 hours.',
      },
    ],
  },
};

export type ServiceDeepContentKey = keyof typeof SERVICE_DEEP_CONTENT;
